Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Kangdai, a company in the medical device industry, which is currently facing challenges with a lower-than-average PE ratio compared to its peers [1][2] - As of May 22, Kangdai's closing price was 7.35 yuan, with a rolling PE ratio of 14.90 times and a total market capitalization of 3.21 billion yuan [1] - The average PE ratio for the medical device industry is 48.71 times, with a median of 35.37 times, placing Kangdai at the 34th position within the industry [1][2] Group 2 - As of the first quarter of 2025, seven institutions hold shares in Kangdai, with a total of 197.34 million shares valued at 1.446 billion yuan [1] - Kangdai's main business includes the research, production, sales, and service of medical devices such as puncture needles and infusion devices, with a diverse product range [1] - The latest financial report for the first quarter of 2025 shows Kangdai achieved a revenue of 548 million yuan, a year-on-year decrease of 3.82%, and a net profit of 60.70 million yuan, a year-on-year increase of 0.28%, with a gross profit margin of 32.02% [1]

5月20日，康德莱今日收盘7.46元，上涨1.08%，滚动市盈率PE（当前股价与前四季度每股收益总和的比 值）达到15.12倍，创30天以来新低，总市值32.58亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入5.48亿元，同比-3.82%；净利润6070.42万元，同 比0.28%，销售毛利率32.02%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)35康德莱15.1215.131.2532.58亿行业平均 49.5147.734.57106.36亿行业中值36.1737.202.5148.58亿1天益医疗-1784.15-3056.061.9022.74亿2澳华内 镜-619.74310.834.9665.31亿3诺唯赞-415.76-491.732.2888.97亿4爱朋医疗-370.37281.374.4630.39亿5博晖 创新-330.72524.813.5348.52亿6硕世生物-137.27-2005.841.2340.15亿7奥精医疗-130.15-190.761.7224.15亿 8睿昂基因-105.86-86.911.5013.70亿9康泰医学-86.99-73. ...